Futura Medical Partners with Market Performance Group, Pivoting from Haleon for US Eroxon Launch

LONDON — Futura Medical has announced a strategic shift in its commercialization plans for Eroxon, its flagship fast-acting erectile dysfunction (ED) gel. The UK-based pharmaceutical developer is transitioning its US distribution and marketing strategy from consumer healthcare giant Haleon to Market Performance Group (MPG), a leading retail consulting and sales management agency. This pivot represents a significant change in direction for Futura as it seeks to capture a dominant share of the lucrative US over-the-counter (OTC) sexual health market.

Eroxon made headlines in mid-2023 when it received landmark FDA clearance as the first clinically proven, topical gel treatment for erectile dysfunction available without a prescription. While Haleon was initially positioned to spearhead the product's highly anticipated launch in the United States, Futura decided that a more agile, dedicated partner was necessary to optimize retail placement and consumer adoption. MPG, which specializes in launching and scaling healthcare brands across mass, drug, food, and e-commerce channels, will now assume full responsibility for commercial execution, including sales, logistics, and retail marketing.

"This transition to Market Performance Group allows us to adopt a highly focused, direct-to-retail approach in the critical US market," said James Barder, Chief Executive Officer of Futura Medical. "MPG's deep expertise in navigating the complex OTC retail landscape and their proven track record of scaling consumer health brands will ensure Eroxon receives the dedicated resources and specialized attention required to maximize its commercial potential."

Strategic Implications for the OTC Market

Under the terms of the new agreement, Futura is poised to retain a larger portion of the economics from US sales compared to its previous licensing structure with Haleon. Industry analysts view the move as a growing trend among mid-sized biotech and pharmaceutical firms opting for specialized commercialization partners over traditional big-pharma licensing deals.

• Enhanced Margin Potential: By bypasssing a multi-layered multinational licensing structure, Futura stands to capture higher profit margins on US sales.
• Targeted Retail Execution: MPG’s specialized broker network offers direct access to key decision-makers at major US retailers like CVS, Walgreens, and Walmart.
• Agile Marketing: The shift allows for more rapid adjustments to consumer feedback and regional demand patterns compared to the rigid frameworks of larger corporations.

With the US sexual wellness sector projected to grow rapidly, market onlookers will be watching closely to see if MPG’s tailored retail execution can successfully position Eroxon as a household name in a market historically dominated by prescription oral medications.